Findings of a systematic
literature review conducted at the University of Maryland in Baltimore show
that addition of estrogen reduced schizophrenia symptoms in women with
schizophrenia in a dose-dependent, and statistically significant, manner
compared with stand-alone antipsychotic treatment.
According to the findings
presented at the 2019 annual meeting of the American Psychiatric Association
(APA), young women typically develop symptoms 3 to 4 years later than their
male counterparts. Also, symptoms in women can develop at times of hormonal
change, including during the postpartum or postmenopausal periods.
Schizophrenia affects about 1%
of the population. Evidence has shown that although the prevalence of
schizophrenia is similar in men and women, the presentation differs.
Overall the levels of estrogen
are typically lower in women with schizophrenia than their counterparts without
the disorder. Estrogen enhances dopamine antagonists in animal models and may
serve as a “natural antipsychotic agent”. It may also have a protective role in
neuronal injury by promoting neurogenesis and re-myelination.
Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of
Medical Associations in Asia and Oceania
(CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of
India
Past National President
IMA
No comments:
Post a Comment